Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study

作者：Yuan Yang, Zengwei Tang, Yuzhou Huang, Qinglin Hu, Shuqing Wang, Ji Jiang, Yali Du, Chen Yang, Miao Chen, Shimin Hu, Bing Han · 发表于：Blood Cancer Journal · 年份：2023 · DOI：10.1038/s41408-023-00845-3 · 被引用次数：6 · 研究领域：Parvovirus B19 Infection Studies、Blood groups and transfusion、Erythrocyte Function and Pathophysiology

Pure red cell aplasia (PRCA) is characterized by normocytic normochromic anemia, reticulocytopenia, and absence of erythroid precursors in the bone marrow [ 1 ]. It can be classified into congenital or acquired PRCA (aPRCA) according to the pathogenesis and etiologies. Acquired PRCA can be further stratified into primary and secondary ones [ 2 ]. aPRCA can be secondary to a variety of diseases including thymoma, large granular lymphocytic leukemia, parvovirus B19 infection, drug uses, hematological or immune diseases, solid tumors, etc [ 2 , 3 ]. Primary aPRCA refers to those with no detectable underlying diseases [ 2 , 4 ].